Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | UNG | P13051 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.51 |
| ▸ | CA7 | P43166 | 4/20 | 0.51 |
| ▸ | CA9 | Q16790 | 4/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820806 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL43683 | 0.84 | NPC1 (0.65) | SMN1; SMN2ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL47068 | 0.81 | ALDH1A1 (0.61) | ALDH1A1UNGRAB9APOLBCYP4F2 | |
| SCHEMBL29677467 | 0.81 | ALDH1A1 (0.61) | ALDH1A1UNGRAB9APOLBCYP4F2 | |
| SCHEMBL2223597 | 0.79 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL16217665 | 0.78 | UNG (0.47) | SMN1; SMN2ALDH1A1UNGNPC1RAB9A | |
| SCHEMBL28346784 | 0.77 | UNG (0.61) | SMN1; SMN2ALDH1A1UNGNPC1RAB9A | |
| SCHEMBL20306092 | 0.77 | UNG (0.61) | SMN1; SMN2ALDH1A1UNGKMT2APOLB | |
| SCHEMBL30678268 | 0.77 | NPC1 (0.62) | SMN1; SMN2ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL161683 | 0.77 | NPC1 (0.58) | SMN1; SMN2ALDH1A1NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729149-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
| US-4031104-A | ANTIHYPERTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-06-21 | — | — | US | disclosed |
| US-4020178-A | 1,4-Dihydropyridine esters used as coronary dilators and anti-hypertensives | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-26 | — | — | US | disclosed |
| US-3996234-A | CORONARY VESSEL DILATORS, HYPOTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
| US-3974278-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3974275-A | 1,4-Dihydropyridine carboxylic acid esters useful as coronary vessel dilators and anti-hypertensives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3971796-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
| US-3966948-A | Spasmolytic, vaso-dilating and anti-hypertensive compositions and methods | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | disclosed |
| US-3946028-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
| US-3946027-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
| US-3943140-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | SMN1; SMN2 1087/4885ALDH1A1 2656/4885UNG 4710/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | SMN1; SMN2 1295/4885ALDH1A1 2495/4885UNG 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.